Braveheart Bio (NASDAQ:BRVE) Insider Michele Anderson Acquires 1,111 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) insider Michele Anderson purchased 1,111 shares of Braveheart Bio stock in a transaction dated Friday, August 7th. The stock was acquired at an average cost of $18.00 per share, with a total value of $19,998.00. Following the completion of the acquisition, the insider directly owned 332,161 shares in the company, valued at approximately $5,978,898. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Braveheart Bio Stock Up 0.7%

Shares of BRVE stock opened at $30.00 on Friday. Braveheart Bio, Inc. has a 1-year low of $28.47 and a 1-year high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.